Acquisition by Mahal Jeetinder Singh of 40000 shares of Jasper Therapeutics subject to Rule 16b-3

JSPR Stock  USD 23.24  0.61  2.70%   
Slightly above 53% of Jasper Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Jasper Therapeutics suggests that many traders are impartial. Jasper Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Jasper Therapeutics. Many technical investors use Jasper Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Jasper Therapeutics Inc officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
Jasper insider trading alert for grant of stock option right to buy by Mahal Jeetinder Singh, Chief Operating Officer, on 20th of February 2024. This event was filed by Jasper Therapeutics Inc with SEC on 2024-02-20. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Jasper Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Jasper Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Jasper Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Jasper Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Jasper Therapeutics Fundamental Analysis

We analyze Jasper Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jasper Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jasper Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Target Price

Target Price Comparative Analysis

Jasper Therapeutics is currently under evaluation in target price category among its peers.

Jasper Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Jasper Therapeutics stock to make a market-neutral strategy. Peer analysis of Jasper Therapeutics could also be used in its relative valuation, which is a method of valuing Jasper Therapeutics by comparing valuation metrics with similar companies.

Peers

Jasper Therapeutics Related Equities

HOOKHookipa Pharma   6.90   
0%
100.0%
ABOSAcumen Pharmaceuticals   2.73   
0%
39.0%
INZYInozyme Pharma   2.64   
0%
38.0%
XLOXilio Development   2.02   
0%
29.0%
ORICOric Pharmaceuticals   1.73   
0%
25.0%
INBXInhibrx   1.17   
0%
16.0%
EWTXEdgewise Therapeutics   0.37   
0%
5.0%
ELDNEledon Pharmaceuticals   0.24   
0%
3.0%
EPIXESSA Pharma   1.10   
15.0%
0%
IKNAIkena Oncology   1.17   
16.0%
0%
EQEquillium   1.28   
18.0%
0%
ELYMEliem Therapeutics   1.30   
18.0%
0%
DSGNDesign Therapeutics   2.93   
42.0%
0%
LYRALyra Therapeutics   5.00   
72.0%
0%

Additional Tools for Jasper Stock Analysis

When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.